biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 12/2021 | 31-03-2021 | Zakończenie certyfikacyjnych badań klinicznych systemu PCR|ONE panel MRSA/MSSA

Previous PostRAPORT ESPI 11/2021 | 31-03-2021 | Rozpoczęcie przedrejestracyjnych testów klinicznych systemu PCR|ONE panel SARS-CoV-2 w nowym ośrodku klinicznymNext PostRAPORT ESPI 13/2021 | 01-04-2021 | Rozpoczęcie walidacji systemu BacterOMIC w zewnętrznym laboratorium

0Shares

Related Posts

Edocera develops device prototype and confirms its ability to detect signs of stroke

SCOPE FLUIDICS0

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

SCOPE FLUIDICS0

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved